Role of Nonsteroidal Anti-inflammatory Drug in Treatment of Extra-abdominal Desmoid Tumors.
10.4055/cios.2018.10.2.225
- Author:
Ja Young CHO
1
;
Sanjay GUPTA
;
Hwan Seong CHO
;
Min Suk PARK
;
Su Jung MOK
;
Ilkyu HAN
;
Han Soo KIM
Author Information
1. Department of Surgery, Lin Women's Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Extra-abdominal desmoid tumors;
Nonsteroidal anti-inflammatory drug
- MeSH:
Cyclooxygenase 2;
Fibromatosis, Aggressive*;
Humans;
Response Evaluation Criteria in Solid Tumors;
Retrospective Studies
- From:Clinics in Orthopedic Surgery
2018;10(2):225-233
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: We retrospectively reviewed the outcomes of patients who had been treated with meloxicam for the extra-abdominal desmoid tumors and evaluated the correlation between clinical outcome and clinic pathological variables. METHODS: Twenty patients treated with meloxicam were followed up every 3 to 6 months. Meloxicam administration was planned at 15 mg/day orally for 6 months. RESULTS: Of the 20 patients evaluated, according to Response Evaluation Criteria in Solid Tumors criteria, there were five patients with partial response (25.0%), eight with stable disease (40.0%), and seven with tumor progression (35.0%). The cumulative probability of dropping out from our nonsurgical strategy using meloxicam was 35.0% at 1 year and 35.0% at 5 years. CONCLUSIONS: The present study suggests that conservative treatment would be a primary treatment option for this perplexing disease even though we were not able to determine that the use of a cyclooxygenase-2 inhibitor would have an additional influence on the natural course of a desmoid tumor.
